| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 6th October 2020 | John L Lamattina | 46,388 | Conversion of derivative | $0.00 | |
| 26th June 2020 | Thomas Edward Hamilton | 159,433 | Other acquisition or disposition | $0.00 | |
| 26th June 2020 | Carole Ben Maimon | 25,083 | Other acquisition or disposition | $0.00 | |
| 26th June 2020 | Thomas Edward Hamilton | 133,420 | Other acquisition or disposition | $0.00 | |
| 26th June 2020 | Therapeutics Holdings, Llc Chondrial | 6,091,242 | Other acquisition or disposition | $0.00 | |
| 10th June 2020 | John L Lamattina | 831 | Grant/award etc. | $0.00 | |
| 15th May 2020 | Thomas Edward Hamilton | 200,000 | Open or private purchase | $5.96 | $1,192,920.00 |
| 17th December 2019 | Robert J Perez | 2,500 | Disposition due to a tender of shares in a change of control transaction | $114.50 | $286,250.00 |
| 1st August 2019 | John L Lamattina | 847 | Payment by withholding | $95.58 | $80,958.29 |
| 1st August 2019 | John L Lamattina | 2,500 | Exercise of derivative | $32.30 | $80,750.00 |
Zafgen
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Zafgen, Inc. is a biopharmaceutical company. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases.
Ticker: ZFGN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1374690
Employees: 7
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.